Friday 24 May 2019 ,
Friday 24 May 2019 ,
Latest News
  • Parliament gets Tk 328 cr budget for FY20
  • Modi claims victory, vows to build 'inclusive' India
  • Mobile networks in Asia, Europe suspending Huawei smartphones order
  • ADB provides $400mn loan for Ctg-Cox’s Bazar rail link
  • Maintain discipline on roads during Eid: Quader
  • HC summons BFSA chief over substandard foods
16 April, 2019 00:00 00 AM

FDA approves Dovato (dolutegravir/lamivudine) for HIV-1 infection

drugs.com
FDA approves Dovato (dolutegravir/lamivudine) for HIV-1 infection

ViiV Healthcare recently announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the treatment of HIV-1 infection in adults with no antiretroviral (ARV) treatment history and with no known resistance to either DTG or 3TC. Dovato, a two-drug regimen (2DR), reduces exposure to the number of ARVs from the start of treatment, while still maintaining the efficacy and high barrier to resistance of a traditional DTG-based three-drug regimen.

Deborah Waterhouse, CEO, ViiV Healthcare, said: “Building on our innovative portfolio of medicines, Dovato is powered by dolutegravir, an antiretroviral included in multiple combination therapies and the most prescribed integrase inhibitor in the world, 2 coupled with the established profile of lamivudine. With Dovato, the first complete, single-tablet, two-drug regimen for treatment-naïve adults, ViiV Healthcare is delivering what patients are requesting—a chance to treat their HIV-1 infection with as few drugs as possible, marking a significant step in HIV treatment.”

The approval of Dovato is supported by the landmark global GEMINI 1 and 2 studies that included more than 1,400 HIV-1 infected adults. In these studies, DTG + 3TC demonstrated non-inferiority based on plasma HIV-1 RNA <50 copies per milliliter (c/mL), a standard measure of HIV-1 control, at Week 48 when compared to a three-drug regimen of DTG and two nucleoside reverse transcriptase inhibitors (NRTIs), tenofovir disoproxil fumarate/ emtricitabine (TDF/FTC), in treatment-naïve, HIV-1 infected adults. The safety results for DTG + 3TC seen in GEMINI 1 and 2 were consistent with the product labelling for DTG and 3TC. No patient who experienced virologic failure in either treatment arm developed treatment-emergent resistance.

Pedro Cahn, principal investigator for the GEMINI study program said: “People are now living longer with HIV and will spend a lifetime taking drugs to suppress their virus. The approval of the fixed dose combination of dolutegravir and lamivudine, a complete, single-tablet, two-drug regimen, marks a pivotal moment in the treatment of HIV-1.

Treatment-naïve people living with the virus have a powerful option that delivers non-inferior efficacy to a dolutegravir-based three-drug regimen, allowing them to take fewer ARVs and get and remain suppressed.”

Jeff Berry, Test Positive Aware Network (TPAN), said: “The approval of Dovato is a welcome paradigm shift, as it brings an innovative treatment approach to newly diagnosed adults with HIV-1. By exposing patients to fewer drugs at the start of treatment, the hope is to help address concerns arising from overall management of prolonged ARV therapy.”

About Dovato (dolutegravir/ lamivudine)

Dovato is approved as a complete regimen for the treatment of HIV-1 infection in adults with no known antiretroviral treatment history and with no known substitutions associated with resistance to either dolutegravir or lamivudine.

Dovato is a once-daily, single-tablet, two-drug regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay, 50 mg) with the nucleoside analogue reverse transcriptase inhibitor (NRTI) lamivudine (Epivir, 300 mg).

Like a DTG-based three-drug regimen, Dovato uses only two drugs to inhibit the viral cycle at two different sites. INSTIs, like dolutegravir, inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic infection. Lamivudine is an NRTI that works by interfering with the conversion of viral RNA into DNA which in turn stops the virus from multiplying.

GEMINI 1 and 2 study design

GEMINI 1 (204861) and GEMINI 2 (205543) are duplicate, Phase III, randomized, double-blind, multicenter, parallel group, non-inferiority studies. These studies evaluate a two-drug regimen of dolutegravir and lamivudine compared with a three-drug, first-line regimen of DTG + TDF/FTC in HIV-1 infected, antiretroviral therapy (ART)-naïve adult participants with baseline HIV-1 viral loads up to 500,000 copies per milliliter. The trials are designed to study the efficacy and safety of once-daily dolutegravir and lamivudine compared to once-daily dolutegravir and the fixed-dose combination of TDF/FTC at 48 weeks in HIV-1-infected, ART-naïve adult participants.

Important safety information

The following ISI is based on the Highlights section of the Prescribing Information for Dovato. Please consult the full Prescribing Information for all the labeled safety information for Dovato.

Warning: patients co-infected with hepatitis b virus (hbv) and human immunodeficiency virus (hiv-1): emergence of lamivudine-resistant hbv and exacerbations of  HBV

All patients with HIV-1 should be tested for the presence of HBV prior to or when initiating Dovato. Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported.

If Dovato is used in patients co-infected with HIV-1 and HBV, additional treatment should be considered for appropriate treatment of chronic HBV; otherwise, consider an alternative regimen.

Severe acute exacerbations of HBV have been reported in patients who are co-infected with HIV-1 and HBV and have discontinued lamivudine, a component of Dovato. Closely monitor hepatic function in these patients and, if appropriate, initiate anti-HBV treatment

Contraindications

Prior hypersensitivity reaction to dolutegravir or lamivudine.

Coadministration with dofetilide.

Warnings and precautions

Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported with dolutegravir. Discontinue Dovato immediately if signs or symptoms of hypersensitivity reactions develop, as a delay in stopping treatment may result in a life-threatening reaction.

Hepatotoxicity has been reported in patients receiving a dolutegravir-containing regimen. Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with Dovato. Monitoring for hepatotoxicity is recommended.

Embryo-fetal toxicity may occur when used at the time of conception and in early pregnancy. Avoid use of Dovato at the time of conception through the first trimester of pregnancy due to the risk of neural tube defects. Advise individuals of childbearing potential to use effective contraception.

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues.

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy.

Adverse reactions

The most common adverse reactions (all grades) observed in ≥2% (in those receiving Dovato) were headache, diarrhea, nausea, insomnia, and fatigue.

Drug interactions

Dovato is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral drugs for the treatment of HIV-1 infection is not recommended.

Refer to the full prescribing information for important drug interactions with Dovato.

Use in specific populations

Pregnancy: Avoid use of Dovato at the time of conception through the first trimester due to the risk of neural tube defects.

Lactation: Breastfeeding is not recommended due to the potential for HIV-1 transmission.

Females and males of reproductive potential: Pregnancy testing and contraception are recommended in individuals of childbearing potential.

Renal Impairment: Dovato is not recommended in patients with creatinine clearance less than 50 mL/min.

Hepatic Impairment: Dovato is not recommended in patients with severe hepatic impairment (Child-Pugh Score C).

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Irritable Bowel Syndrome or IBS is a disorder characterised most commonly by cramping, abdominal pain, bloating, constipation and diarrhea. IBS causes…
FAQ on Irritable Bowel Syndrome

FAQ on Irritable Bowel Syndrome

IBS affects between 25 and 45 million Americans. Most of them are women. People are most likely to get the condition in their late teens to early 40s.…
Irritable bowel syndrome (IBS): a long-term gastrointestinal disorder

Irritable bowel syndrome (IBS): a long-term gastrointestinal disorder

CHRISTIAN NORDQVIST Irritable bowel syndrome, or irritable bowel disease, is a long-term gastrointestinal disorder. It causes abdominal pain, bloating,…
Coping with IBS

Coping with IBS

Coping with irritable bowel syndrome (IBS) presents a number of daily challenges. While there is no cure for the disorder, treatments are available. Learn…
12 Foods to avoid with IBS

12 Foods to avoid with IBS

A healthy diet generally consists of eating a wide variety of nutritious foods in moderation. If you have irritable bowel syndrome (IBS), you may notice…
Bowel movement disorders

Bowel movement disorders

Bowel (intestinal) function varies greatly not only from one person to another but also for any one person at different times. It can be affected by diet,…
Type 2 diabetes: losing even a small amount of weight may lower heart disease risk

Type 2 diabetes: losing even a small amount of weight may lower heart disease risk

People with type 2 diabetes are often encouraged to lose weight. And recent studies have shown that losing a lot of weight can reverse diabetes, meaning…
Autism estimates for the USA are wildly inaccurate, say experts at INSAR 2019

Autism estimates for the USA are wildly inaccurate, say experts at INSAR 2019

SALLY ROBERTSON The Centers for Disease Control and Prevention (CDC) has released new statistics on autism. They estimate that there has been a 15% increase…
Biochemical compound responsible for blood pressure drop in sepsis

Biochemical compound responsible for blood pressure drop in sepsis

MARIA FERNANDA ZIEGLER International research group demonstrates the involvement of singlet molecular oxygen in vasodilation, causing a sharp decline…
icddr,b launches artificial intelligence based  diabetic retinopathy detection

icddr,b launches artificial intelligence based diabetic retinopathy detection

Recently, icddr,b in collaboration with Eyes For All PLC, United Arab Emirates and DIAGNOS Inc, Canada have launched an artificial intelligence (AI) based…
Hospitals to test mums-to-be for risky group-B strep

Hospitals to test mums-to-be for risky group-B strep

Screening for a life-threatening bacterial infection affecting newborn babies is to be offered at 80 hospitals in England, Wales and Scotland. About 150,000…
FDA approves Dengvaxia (dengue vaccine) for the prevention of dengue disease in endemic regions

FDA approves Dengvaxia (dengue vaccine) for the prevention of dengue disease in endemic regions

The U.S. Food and Drug Administration announced recently the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting